Thermo Fisher Scientific Inc. (NYSE:TMO) has earned an average recommendation of “Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $353.50.

Several research firms have commented on TMO. Needham & Company LLC boosted their target price on shares of Thermo Fisher Scientific from $341.00 to $383.00 in a research report on Thursday, April 23rd. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $365.00 to $390.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Finally, SVB Leerink upped their price objective on shares of Thermo Fisher Scientific from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, April 23rd.

In related news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $348.00, for a total value of $870,000.00. Following the completion of the transaction, the chief financial officer now directly owns 37,989 shares of the company’s stock, valued at $13,220,172. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total transaction of $9,990,600.00. Following the completion of the transaction, the chief executive officer now directly owns 304,946 shares of the company’s stock, valued at $101,553,116.92. The disclosure for this sale can be found here. Insiders sold 97,500 shares of company stock worth $33,044,350 over the last quarter. 0.44% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Kovitz Investment Group Partners LLC boosted its position in Thermo Fisher Scientific by 4.0% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 802 shares of the medical research company’s stock worth $261,000 after purchasing an additional 31 shares during the period. Capital Bank & Trust Co boosted its position in Thermo Fisher Scientific by 2.1% during the fourth quarter. Capital Bank & Trust Co now owns 1,509 shares of the medical research company’s stock worth $490,000 after purchasing an additional 31 shares during the period. Tiedemann Advisors LLC boosted its position in Thermo Fisher Scientific by 1.4% during the first quarter. Tiedemann Advisors LLC now owns 2,169 shares of the medical research company’s stock worth $616,000 after purchasing an additional 31 shares during the period. Miracle Mile Advisors LLC boosted its position in Thermo Fisher Scientific by 3.2% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,077 shares of the medical research company’s stock worth $350,000 after purchasing an additional 33 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its position in Thermo Fisher Scientific by 1.6% during the first quarter. Sequoia Financial Advisors LLC now owns 2,613 shares of the medical research company’s stock worth $741,000 after purchasing an additional 41 shares during the period. 87.65% of the stock is owned by hedge funds and other institutional investors.

TMO stock traded up $10.26 during trading hours on Friday, hitting $361.06. The company’s stock had a trading volume of 35,326 shares, compared to its average volume of 1,479,945. The company has a quick ratio of 1.69, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $138.55 billion, a PE ratio of 39.33, a price-to-earnings-growth ratio of 2.36 and a beta of 1.04. Thermo Fisher Scientific has a 12 month low of $250.21 and a 12 month high of $358.00. The stock has a 50 day moving average price of $345.07 and a two-hundred day moving average price of $325.04.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.79 by $0.15. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6.18 billion. Thermo Fisher Scientific had a net margin of 14.31% and a return on equity of 17.25%. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.81 earnings per share. Sell-side analysts expect that Thermo Fisher Scientific will post 11.9 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.22 dividend. The ex-dividend date is Friday, June 12th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.24%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.13%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Commodities

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.